All the news Showing 10 of 51 articles from: NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Fatty liver disease may increase risk of severe COVID-19 disease Keith Alcorn / 27 April 2020 A preliminary analysis of people admitted to hospital in China with COVID-19 symptoms shows that people with non-alcoholic fatty liver disease (NAFLD) were six times more likely to progress to severe COVID-19 ... HIV-positive people with fatty liver disease are at high risk for fibrosis Liz Highleyman / 23 March 2020 People living with HIV who have non-alcoholic fatty liver disease (NAFLD) often have liver fibrosis and are at risk for fibrosis worsening, researchers reported earlier this month at the Conference ... Global burden of deaths and liver cancer due to non-alcoholic fatty liver disease growing Keith Alcorn / 11 December 2019 Non-alcoholic fatty liver disease is a growing cause of liver cancer and death in some regions of the world, an analysis of global reporting on liver disease shows. The findings ... New NASH therapies show promise in mid-stage studies Liz Highleyman / 26 November 2019 Phase II study results presented at the AASLD Liver Meeting this month in Boston show that a number of experimental therapies improve markers of liver health in people with non-alcoholic steatohepatitis (NASH). ... People with fatty liver disease struggle to lose weight Liz Highleyman / 25 November 2019 Losing weight may be especially difficult for people with fatty liver disease due to differences in their metabolism. But nonetheless, some can succeed and doing so improves liver health, according to studies ... Emricasan and selonsertib fail to improve fibrosis in people with NASH Liz Highleyman / 12 November 2019 A pair of experimental therapies for non-alcoholic steatohepatitis (NASH) failed to offer notable improvements in controlled clinical trials, despite having shown promising effects on liver biomarkers in earlier studies. Dr Stephen Harrison ... Tesamorelin reduces liver fat and fibrosis progression in people with HIV and NAFLD Keith Alcorn / 21 October 2019 Treatment with tesamorelin, a synthetic growth hormone-releasing hormone, reduced liver fat content and reduced the progression of liver fibrosis in people with HIV who had non-alcoholic fatty liver disease (NAFLD), researchers report ... Non-alcoholic fatty liver disease raises the risk of cancer in overweight people Keith Alcorn / 24 September 2019 Obesity without non-alcoholic fatty liver disease (NAFLD) does not raise the risk of cancer, but people with NAFLD who are also obese are almost twice as likely to be diagnosed with cancer ... Fatty liver raises the risk of death in people with HIV and hepatitis C Keith Alcorn / 15 September 2019 People with HIV and hepatitis C co-infection who had fatty liver disease were twice as likely to die during a five-year follow-up period as their counterparts without fatty liver disease, ... Emricasan misses study endpoint for improving portal hypertension in people with NASH Liz Highleyman / 24 April 2019 The experimental caspase inhibitor emricasan did not meet the statistical threshold for improvement of portal hypertension in people with non-alcoholic steatohepatitis (NASH), but it did appear to have some benefit for those at ... ← Prev12345...6Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive